Giuseppe Lanzarone

Dr. Giuseppe Lanzarone

Unit of Hematology, Department of Oncology, University of Torino, Turin, Italy
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2025 in Cancers
Verified
Journal Article
Open access
PDF file
ECElena Crisa
Elena Crisa
IDIrene Dogliotti
Irene Dogliotti
GLGiuseppe Lia
Giuseppe Lia
MCMarco Cerrano
Marco Cerrano
EAErnesta Audisio
Ernesta Audisio
BBBENEDETTO BRUNO
BENEDETTO BRUNO
Background/Objectives. Recent evidence underscores the prognostic and classificatory relevance of somatic mutations in myelodysplastic neoplasms (MDSs) and acute myeloid leukemia (AML). Methods. This prospective study assessed gene mutation dynamics via next-generation sequencing (NGS) in 84 MDS/AML patients treated with intensive chemotherapy or hypomethylating agents plus venetoclax. Results. At diagnosis, 95% had somatic mutations detected by NGS, while only 29% had a measurable residual disease (MRD) marker with qPCRs. NGS at complete remission (CR) was performed in 56/71 patients who achieved CR; 59% had persisting mutations, mostly in DNMT3A, TET2, and ASXL1 (DTA mutations). Mutations’ persistence in CR was linked to a shorter relapse-free survival (RFS; median 8 months vs. not reached, HR 4.41, 95% CI 1.69–11.49; p = 0.002) and overall survival (OS; 2-year OS: 51.5% vs. 88%, HR 4.02, 95% CI 1.39–11.65; p = 0.001). Combining NGS and multiparameter flow cytometry (MFC) for MRD detection, we divided patients into three groups with distinct RFS (NGS−/MFC−, NGS−/MFC+, or NGS+/MFC− and NGS+/MFC+), with double-negative patients displaying the best RFS (p < 0.001). In the multivariate analysis, NGS and MFC MRD+ were independent predictors of RFS. Conclusions. This real-world study confirms the added prognostic role of NGS in MRD detection on RFS, particularly when combined with MFC. This approach may improve risk stratification and guide treatment decisions.

16 December 2022 in European Journal of Haematology
Verified
Journal Article
Open access
EIElena Inzoli
Elena Inzoli
ECElena Crisa
Elena Crisa
NPNovella Pugliese
Novella Pugliese
ICIvan Civettini
Ivan Civettini
GLGiuseppe Lanzarone
Giuseppe Lanzarone
Elena Maria ElliElena Maria Elli
Elena Maria Elli
Objectives: Erythropoiesis-stimulating agents (ESA) have an established role in treating anemia in hematological malignancies. However, their role, particularly biosimilar ESA (B-ESA), in myelofibrosis (MF) is not well established.Methods: This study retrospectively collected data on 96 MF patients treated with B-ESA (alpha/zeta) for the management of anemia to assess safety, efficacy (anemia response [AR]), and survival.Results: Seventy-seven patients (80%) obtained AR. The median time to AR was 2.5 months. In multivariate analysis, significant predictive factors of AR were transfusion independency (p = .006) and ferritin levels < 200 ng/ml (p = .009) at baseline. After a median follow-up of 43.8 months from diagnosis, 38 patients (39%) died, 11 (28.9%) from leukemic evolution. Only two patients (2.5%) stopped B-ESA for toxicity. The 24-month survival was significantly affected by response to B-ESA (70.8% in AR vs. 55.3% in non-responder patients, p = .016). In multivariate analysis, age & LE; 70 years (p = .029) and Hb > 8.5 g/dl (p = .047) at baseline were significantly associated with improved survival, with a trend for longer survival in AR patients (p = .06).Conclusions: B-ESA seems to be an effective and well-tolerated option for anemia treatment in the MF setting. This strategy deserves further clinical investigation.

9 August 2021 in Medicina
Verified
Journal Article
Open access
PDF file
GLGiuseppe Lanzarone
Giuseppe Lanzarone
MOMatteo Olivi
Matteo Olivi
Myeloproliferative neoplasms (MPNs) are clonal stem cell disorders characterized collectively by clonal proliferation of myeloid cells with variable morphologic maturity and hematopoietic efficiency. Although the natural history of these neoplasms can be measured sometimes in decades more than years, the cytogenetics analysis can offer useful information regarding the prognosis. Cytogenetics has a well-established prognostic role in acute leukemias and in myelodysplastic syndromes, where it drives the clinical decisions. NGS techniques can find adverse mutations with clear prognostic value and are currently included in the prognostic evaluation of MPNs in scores such as MIPSS, GIPSS, MIPSS-PV, and MIPSS-ET. We suggest that cytogenetics (considering its availability and relative cost) has a role regarding prognostic and therapeutic decisions.

2 July 2025 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
MCMaria Crocioni
Maria Crocioni
CNCarlotta Nardelli
Carlotta Nardelli
AFAnair Graciela Lema Fernandez
Anair Graciela Lema Fernandez
VPValentina Pierini
Valentina Pierini
EFEmanuela Falcinelli
Emanuela Falcinelli
CMCristina Mecucci
Cristina Mecucci